KEY TAKEAWAYS
- The study aimed to investigate the safety and efficacy of intraperitoneal irrigation chemotherapy with lobaplatin in treating advanced GC.
- Researchers noticed that intraperitoneal irrigation chemotherapy with lobaplatin is well-tolerated and safe for patients with advanced GC.
Jing Zhang and the team aimed to evaluate the safety and efficiency of intraperitoneal irrigation chemotherapy with lobaplatin for the treatment of advanced gastric cancer (GC).
They performed an inclusive analysis of 56 patients with locally advanced GC who received intraoperative intraperitoneal irrigation chemotherapy with lobaplatin in addition to undergoing radical D2 surgery. These patients were matched 1:1 based on 8 covariates to a control group of 56 patients who did not receive the drug treatment. Clinical data from both groups were systematically collected and analyzed to evaluate the safety and efficiency of the intraperitoneal chemotherapy approach.
The 2 groups were well-balanced in basic characteristics and had comparable clinical indices. All patients had similar time to first flatus (2.8 ± 0.3 vs. 2.9 ± 0.3 d, P = 0.076), time to first oral intake (3.5 ± 3.4 vs. 4.1 ± 4.6 d, P = 0.439), and duration of postoperative hospitalization (9.1 ± 3.2 vs. 9.6 ± 4.0 d, P = 0.446).
There were no significant differences in postoperative complications including anastomotic and duodenal stump leakage, abdominal and anastomotic bleeding, seroperitoneum, and incision infection between the experimental and control groups (P > 0.05).
The rates of chemotherapy-related side effects including allergic reaction, neurotoxicity, diarrhea, and nausea/vomiting were also similar between the 2 groups, and there were no abnormalities in leukocyte and platelet levels and liver and renal function during the first 5 days after surgery.
The study concluded that intraperitoneal irrigation chemotherapy with lobaplatin is safe for patients with advanced GC. The analysis revealed no significant differences in postoperative recovery metrics, complications, or chemotherapy-related side effects between the lobaplatin-treated and control groups.
No funding information was given.
Source: https://pubmed.ncbi.nlm.nih.gov/39068574/
Zhang J, Wang P, Sun Y, et al. (2024). “Intraperitoneal Irrigation Chemotherapy with Lobaplatin in Locally Advanced Gastric Cancer: A Special Type of Abdominal Chemotherapy.” Asian Pac J Cancer Prev. 2024 Jul 1;25(7):2409-2413. doi: 10.31557/APJCP.2024.25.7.2409. PMID: 39068574.
